Inhibition of Diseases Associated with Amyloid Formation
Description of Invention:
Amyloid deposition in brain samples is diagnostic for several serious and fatal diseases. These include Alzheimer's disease as well as several transmissible spongiform encephalopathies (TSEs) (prion diseases) such as Creutzfeldt-Jakob disease (CJD) and bovine spongiform encephalopathy (BSE) ("mad cow disease"). Together, these diseases having amyloid depositions are termed amyloidogenic diseases.
This invention covers and discloses the method and compositions of using Congo Red in the treatment of such amyloidogenic diseases. Congo Red is shown to inhibit the accumulation of PrP-res, the amyloidogenic and pathologic protein or the transmissible spongiform encephalopathies. The potential therapeutics covered by this invention includes Congo Red and its derivatives.
Patent Status:
DHHS Reference No. E-107-1992/0 Licensing Status: This technology is no longer available for licensing.
Portfolios: Rare Diseases Infectious Diseases Central Nervous System
Central Nervous System -Therapeutics-Neurological Therapeutics-Alzheimer Infectious Diseases -Therapeutics-Anti-Viral-Non-AIDS (only) Central Nervous System -Therapeutics Infectious Diseases -Therapeutics
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
